104 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
20 Apr 22
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
5:24pm
The analysis performed by Vinbiocare included a review of the available safety data from over 17,000 participants enrolled in the Phase 1, 2 and 3 … portions of the study through one month after second dose of ARCT-154. An independent Data Safety Monitoring Board has performed ongoing review of the safety
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
10 May 21
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
4:21pm
data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3
In negotiations … , and the new interim safety and immunogenicity data from our Phase 2 study, we are looking forward to initiating ARCT-021 Phase 3 study as well
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
1 Sep 22
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of
5:09pm
will use Arcturus’ STARR™ self-amplifying mRNA vaccine platform technology which demonstrated favorable safety and efficacy against SARS-CoV-2 infection … to support preclinical, manufacturing, nonclinical safety studies, along with development and regulatory support for Arcturus’ self-amplifying mRNA
8-K
EX-99.1
ujaqj3
19 Jun 19
Regulation FD Disclosure
9:31am
8-K
EX-99.1
fogn922al54470
9 May 23
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
4:11pm
8-K
EX-99.1
26tgan24xq
7 Nov 19
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
a2s1x6s3 4ft
28 Apr 23
Regulation FD Disclosure
6:00am
8-K
EX-99.1
yns53xg
19 Mar 24
Regulation FD Disclosure
6:00am
8-K
EX-99.1
fukexbeef3ufvw fdty
8 Nov 21
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
4:18pm
8-K
EX-99.1
nh87o7d7 4t
28 Feb 22
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
4:15pm
8-K
EX-99.1
557zl2c jvh6sv
9 May 22
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
4:20pm
8-K
2bekgp0r7n88m ra3o
8 Nov 21
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
4:18pm
8-K
EX-99.1
dejwb5iqc939ybehyqbe
9 Nov 20
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
4:06pm
10-K
4wy6ocq4bb11ox3do3mu
16 Mar 20
Annual report
11:09am